Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Abraxane in Recurrent Ovarian or Peritoneal Cancer
NCT00407563Phase 2Completed
- Sponsor
- Accelerated Community Oncology Research Network
- Start
- Jan 2007
- Primary completion
- Feb 2011
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, nab-paclitaxel in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC), sponsored by Accelerated Community Oncology Research Network. Started Jan 2007; status: completed.
02
Drugs
bevacizumabnab-paclitaxel
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00407563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00407563.